Applying Risk-Based Follow-Up Strategies on the Dutch Breast Cancer Population: Consequences for Care and Costs - Value in Health
A 23 gene–based molecular prognostic score precisely predicts overall survival of breast cancer patients - eBioMedicine
About the Oncoytpe DX Breast Recurrence Score® | Oncotype
Breast Cancer Local Recurrence Risk Calculator
Breast Cancer Prognosis
Residual Cancer Burden Is Prognostic of Outcomes Across Breast Cancer Subtypes - The ASCO Post
Online Breast Calculators
Twenty-one gene panel and calculation of recurrence score. (a) The... | Download Scientific Diagram
Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data - The Breast
New Model Predicts Impact of Post-Mastectomy Radiation on Breast Cancer Survival – Consult QD
Improving Breast Cancer Survival Analysis through Competition-Based Multidimensional Modeling | PLOS Computational Biology
Breast Cancer Prognosis
A new clinical-genomic model to predict 10-year recurrence risk in primary operable breast cancer patients | Scientific Reports
Breast Cancer Prognosis
See @matteolambe's Tweet on Twitter / Twitter
Management of Triple-Negative Breast Cancer in Older Patients: How Is It Different?
Breast Cancer Survival by stage at Diagnosis - Moose and Doc
CTS5 calculator useful to guide decision to extend endocrine therapy in ER-positive breast cancer
Interpreting the Results | Oncotype DX® Test | Oncotype IQ® Canada
What Are My Survival Chances? A Cancer Calculator Does the Math - Cancer Health
New Model Predicts Impact of Post-Mastectomy Radiation on Breast Cancer Survival – Consult QD
Machine learning-based lifetime breast cancer risk reclassification compared with the BOADICEA model: impact on screening recommendations | British Journal of Cancer
Breast Cancer Survival by stage at Diagnosis - Moose and Doc
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
